Xcout Intel
Verge Genomics competitors & alternatives
The 12 closest competitors and alternatives to Verge Genomics among biotech companies — ranked by similarity to what Verge Genomics actually does, not by market-cap band.
Subscribe to see Verge Genomics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Verge Genomics
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Verge Genomics at a glance
Verge Genomics is a biotech company headquartered in United States. Xcout tracks 2 named people at Verge Genomics, including Alice Zhang (CEO). Xcout recorded 1 job posting from Verge Genomics in the last 90 days.
Verge Genomics leadership
- Alice ZhangCEO
- Emily RipkaHead of Product & Engineering
Hiring at Verge Genomics
Xcout recorded 1 job posting from Verge Genomics in the last 90 days, from a hiring record Xcout has kept since May 2026.
The weekly hiring trend, the roles and locations behind it — see Verge Genomics's hiring signals →
Top 12 Verge Genomics competitors
Ranked by semantic similarity — how close each company is to Verge Genomics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Deep Genomics is a biotechnology research company that collaborates across disciplines to solve complex molecular design challenges. The company's corporate headquarters are located in Toronto, Ontario, Canada, a hub for innovation.
Healthtech
GATC Health Corp. is a biotechnology company that uses artificial intelligence, genomics, and toxicology data to discover and develop therapeutics and predict drug safety. Its work is aimed at pharmaceutical and biotechnology partners as well as patients needing treatments for serious diseases.
Similar biotech company
Variant Bio, Inc. is a biotechnology company that uses human genomic diversity and population genetics to discover therapeutic targets and develop medicines. It works with researchers, healthcare and biotechnology partners, and genetically diverse communities to study traits associated with health and disease.
Similar biotech company
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Similar biotech company
NeuroX1 Inc. is a for-profit biotechnology startup founded in 2021 with headquarters in Austin, Texas, operating a target identification and drug discovery platform that utilizes proprietary technology.
Biotechnology
WittGen Inc. provides a virtual cell-to-patient profiling technology powered by single-cell generative AI for clinical leaders and biopharmaceutical researchers. The company's platform transforms archived bulk RNA samples and pathological image data into regulator-ready patient stratification insights and cellular-level biomarkers to de-risk clinical trials and accelerate oncology drug development.
Similar biotech company
Harmonic Discovery is a drug discovery company founded in 2021 and headquartered in New York City. The company leverages machine learning and precision pharmacology to develop therapeutics for complex diseases.
Similar biotech company
Cellarity is a U.S. biotechnology company that uses single-cell biology, computational modeling, and machine learning to discover medicines based on cellular behaviors and disease mechanisms. It serves pharmaceutical and biotechnology development needs, advancing its own therapeutic programs and potentially partnering with other drug developers.
Similar biotech company
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Biotechnology
Engine Biosciences is a Singapore-based biotechnology company and venture-creation platform that combines machine learning, computational biology, and laboratory experimentation to discover and develop new medicines. It builds and invests in therapeutic-focused biotech companies, serving pharmaceutical and healthcare markets.
Biotechnology
SwitchPoint Bio Holding, Inc. operates a platform that combines precision epigenomics and artificial intelligence to analyze cellular biology from blood samples. The company provides biomarker discovery, patient stratification, and treatment response mechanism readouts to support drug development and clinical research.
Biotechnology
Cime Therapeutics Inc. is a chemistry-first company that provides an automated synthesis platform integrating artificial intelligence and machine learning for drug discovery. The company serves the pharmaceutical and biotechnology sectors by producing novel therapeutic molecules, such as small molecules, molecular glues, and covalent compounds, at high speed and scale.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Verge Genomics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Verge Genomicsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →